Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Calmodulin antagonists decrease the binding of epidermal growth factor to transformed, but not to normal, human

P V Bodine, J T Tupper

    The Biochemical Journal
    |March 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Expression and regulation of Runx2/Cbfa1 and osteoblast phenotypic markers during the growth and differentiation of human osteoblasts.

    Journal of cellular biochemistry·2001
    Same author

    Evidence that conditionally immortalized human osteoblasts express an osteocalcin receptor.

    Bone·1999
    Same author

    Suppression of ligand-dependent estrogen receptor activity by bone-resorbing cytokines in human osteoblasts.

    Endocrinology·1999
    Same author

    The ongoing saga of osteoporosis treatment.

    Journal of cellular biochemistry. Supplement·1999
    Same author

    Estrogen receptor-alpha is developmentally regulated during osteoblast differentiation and contributes to selective responsiveness of gene expression.

    Endocrinology·1998
    Same author

    Functional properties of a conditionally phenotypic, estrogen-responsive, human osteoblast cell line.

    Journal of cellular biochemistry·1997
    Same journal

    Mechanistic insights into acetylated histone recognition by the CECR2 bromodomain.

    The Biochemical journal·2026
    Same journal

    Nanobodies against Plasmodium adhesins that block receptor engagement and malaria parasite invasion.

    The Biochemical journal·2026
    Same journal

    Persistence without turnover: the RhoG G12E mutant highlights the role of nucleotide cycling in RhoG signaling.

    The Biochemical journal·2026
    Same journal

    Alternative Splicing of Rice Chloroplastic CuZn Superoxide Dismutase, OsCSD2: Impact on expression and protein characteristics.

    The Biochemical journal·2026
    Same journal

    Difference and similarity between the ubiquitous secretory pathway Ca2+-ATPases, SERCA2b, and SPCA1a.

    The Biochemical journal·2026
    Same journal

    A molecular perspective on dimethylarginine dimethylaminohydrolases structure and function.

    The Biochemical journal·2026
    See all related articles

    Calmodulin antagonists reduced epidermal growth factor (EGF) binding to transformed cells but not normal cells. This suggests calmodulin plays a role in regulating EGF receptor affinity in cancer cells.

    Area of Science:

    • Cell Biology
    • Molecular Pharmacology

    Background:

    • Epidermal Growth Factor (EGF) signaling is crucial for cell growth and is often dysregulated in cancer.
    • Calmodulin is a key calcium-binding protein involved in various cellular processes.
    • Simian virus 40 (SV40)-transformed human fibroblasts (WI38) provide a model for studying cancer-related cellular changes.

    Purpose of the Study:

    • To investigate the role of calmodulin in regulating EGF receptor binding.
    • To determine if calmodulin antagonists affect EGF binding to normal versus transformed cells.

    Main Methods:

    • Utilized four psychoactive agents known to inhibit calmodulin activity.
    • Assessed the binding of 125I-labelled EGF to normal (WI38) and SV40-transformed WI38 human fibroblasts.
    • Examined the dose-dependent effects of calmodulin antagonists on EGF binding.

    Related Experiment Videos

    Main Results:

    • Calmodulin antagonists significantly decreased 125I-labelled EGF binding to SV40-transformed WI38 cells in a dose-dependent manner.
    • No significant effect on EGF binding was observed in normal WI38 cells.
    • The observed decrease in binding suggests a reduction in the apparent affinity of the plasma-membrane EGF receptor for EGF in transformed cells.

    Conclusions:

    • Calmodulin activity appears to influence the affinity of the EGF receptor in transformed cells.
    • Inhibition of calmodulin may represent a potential therapeutic strategy to modulate EGF signaling in cancer.
    • These findings highlight a specific role for calmodulin in the aberrant growth signaling of SV40-transformed fibroblasts.